Erste Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-25,300
| Closed | -$432K | – | 608 |
|
|
2026
Q1 | $432K | Hold |
25,300
| – | – | ﹤0.01% | 525 |
|
|
2025
Q4 | $637K | Hold |
25,300
| – | – | 0.01% | 467 |
|
|
2025
Q3 | $573K | Sell |
25,300
-16,700
| -40% | -$389K | 0.01% | 461 |
|
|
2025
Q2 | $732K | Hold |
42,000
| – | – | 0.01% | 559 |
|
|
2025
Q1 | $1.02M | Hold |
42,000
| – | – | 0.01% | 374 |
|
|
2024
Q4 | $1.37M | Hold |
42,000
| – | – | 0.02% | 357 |
|
|
2024
Q3 | $1.24M | Hold |
42,000
| – | – | 0.01% | 369 |
|
|
2024
Q2 | $1.74M | Hold |
42,000
| – | – | 0.02% | 318 |
|
|
2024
Q1 | $2.46M | Hold |
42,000
| – | – | 0.03% | 284 |
|
|
2023
Q4 | $2.64M | Buy |
42,000
+18,000
| +75% | +$913K | 0.04% | 270 |
|
|
2023
Q3 | $952K | Sell |
24,000
-27,650
| -54% | -$1.21M | 0.02% | 349 |
|
|
2023
Q2 | $4.6M | Buy |
51,650
+12,000
| +30% | +$1.04M | 0.08% | 223 |
|
|
2023
Q1 | $2.62M | Buy |
39,650
+2,650
| +7% | +$153K | 0.05% | 269 |
|
|
2022
Q4 | $1.91M | Hold |
37,000
| – | – | 0.04% | 281 |
|
|
2022
Q3 | $2.42M | Hold |
37,000
| – | – | 0.05% | 266 |
|
|
2022
Q2 | $1.67M | Hold |
37,000
| – | – | 0.04% | 302 |
|
|
2022
Q1 | $1.83M | Hold |
37,000
| – | – | 0.03% | 306 |
|
|
2021
Q4 | $1.75M | Buy |
37,000
+20,000
| +118% | +$787K | 0.03% | 305 |
|
|
2021
Q3 | $577K | Sell |
17,000
-16,900
| -50% | -$950K | 0.01% | 388 |
|
|
2021
Q2 | $2.15M | Hold |
33,900
| – | – | 0.04% | 274 |
|
|
2021
Q1 | $1.43M | Hold |
33,900
| – | – | 0.03% | 311 |
|
|
2020
Q4 | $1.86M | Buy |
+33,900
| New | +$1.43M | 0.05% | 277 |
|
Other funds holding APLS
Erste Asset Management's APLS Position: Q2 2026 in Review
Erste Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 25,300 shares — an estimated $432K sold.
Erste Asset Management first reported a position in APLS in Q4 2020 and held it in 22 quarters. The position peaked at $4.6M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Erste Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Erste Asset Management sold 25,300 Apellis Pharmaceuticals shares in Q2 2026, an estimated $432K.
- Erste Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2020 and held it in 22 quarters.
- Erste Asset Management's Apellis Pharmaceuticals position peaked at $4.6M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.